Pacira BioSciences Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Pacira BioSciences de 29.3% y 8.1% por año respectivamente. Se prevé que el BPA crezca en un 28.5% al año. Se espera que la rentabilidad financiera sea de 16.6% en 3 años.

Información clave

29.5%

Tasa de crecimiento de los beneficios

28.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	7.8%
Rentabilidad financiera futura	16.6%
Cobertura de analistas	Good
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

Sep 17

Pacira Biosciences' EXPAREL average daily sales more than doubles in May

Jun 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PCRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	828	115	260	313	9
12/31/2025	763	89	208	258	10
12/31/2024	693	59	181	223	9
12/31/2023	675	42	139	155	N/A
9/30/2023	666	7	130	149	N/A
6/30/2023	669	-5	127	147	N/A
3/31/2023	669	-10	105	134	N/A
12/31/2022	667	16	115	145	N/A
9/30/2022	654	21	93	126	N/A
6/30/2022	614	39	102	144	N/A
3/31/2022	580	38	104	144	N/A
12/31/2021	542	42	80	126	N/A
9/30/2021	513	62	98	149	N/A
6/30/2021	503	174	83	129	N/A
3/31/2021	443	148	39	83	N/A
12/31/2020	430	146	39	77	N/A
9/30/2020	421	126	28	56	N/A
6/30/2020	408	-10	13	35	N/A
3/31/2020	435	0	58	73	N/A
12/31/2019	421	-11	60	71	N/A
9/30/2019	394	2	58	66	N/A
6/30/2019	372	8	53	64	N/A
3/31/2019	354	7	44	55	N/A
12/31/2018	337	0	34	49	N/A
9/30/2018	321	-4	27	45	N/A
6/30/2018	305	-11	7	25	N/A
3/31/2018	292	-33	-6	15	N/A
12/31/2017	287	-43	-1	18	N/A
9/30/2017	280	-51	N/A	18	N/A
6/30/2017	281	-66	N/A	33	N/A
3/31/2017	280	-54	N/A	37	N/A
12/31/2016	276	-38	N/A	33	N/A
9/30/2016	273	-36	N/A	33	N/A
6/30/2016	267	-11	N/A	26	N/A
3/31/2016	256	-3	N/A	26	N/A
12/31/2015	249	2	N/A	28	N/A
9/30/2015	241	10	N/A	26	N/A
6/30/2015	231	4	N/A	29	N/A
3/31/2015	219	-1	N/A	30	N/A
12/31/2014	198	-14	N/A	27	N/A
9/30/2014	169	-31	N/A	6	N/A
6/30/2014	141	-43	N/A	-13	N/A
3/31/2014	111	-52	N/A	-34	N/A
12/31/2013	86	-64	N/A	-44	N/A
9/30/2013	62	-68	N/A	-58	N/A
6/30/2013	48	-69	N/A	-59	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (29.3% al año) de PCRX es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (29.3% al año) de PCRX crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de PCRX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (8.1% al año) de PCRX crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.1% al año) de PCRX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de PCRX sea baja dentro de 3 años (16.6%).

Pacira BioSciences Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 21%

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Price target decreased by 9.5% to US$55.89

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

Consensus forecasts updated

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Recent updates

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales

Pacira BioSciences Q2 2022 Earnings Preview

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Pacira BioSciences sees Q2 revenue below consensus

Chief Clinical Officer recently sold US$53k worth of stock

Chief Technical Officer exercised options to buy US$322k worth of stock.

Investor sentiment deteriorated over the past week

Chairman & CEO recently sold US$734k worth of stock

Chief Clinical Officer exercised options to buy US$129k worth of stock.

Independent Director recently sold US$59k worth of stock

Consensus EPS estimates fall by 28%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman & CEO exercised options to buy US$1.5m worth of stock.

President of Rest of World exercised options and sold US$861k worth of stock

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022